Icometrix announces ischaemic stroke solution 

3503

In a press release, icometrix announced the addition of icobrain cva, a stroke solution, to the icobrain portfolio. According to the company, this announcement follows clearance from the US Food and Drug Administration (FDA) and CE-marking of its image processing software for the analysis and communication of the tissue perfusion state on computer tomography (CT) perfusion scans in patients with ischaemic stroke. 

According to icometrix, the icobrain cva is a fully-automated software solution for the quantitative assessment of tissue perfusion on CT. The company claims that icobrain cva reports the volume of the core and perfusion lesion by quantifying reduced cerebral blood flow, volume, and transit time. Additionally, icometrix states the report includes information on the correctness of the selected arterial input function and the quality of the output.  

The press release details that icobrain cva provides physicians with fast, fully automated, and state-of-the-art insights to support treatment decisions in acute ischaemic stroke. It is further stated that the automated assessment of tissue parameters in an acute clinical setting by icobrain cva will allow more patients to get the right treatment and can improve patient outcomes and care while increasing efficiency. 

“With the launch of icobrain cva we address a persisting need in the treatment of acute ischaemic stroke. By democratising advanced CT perfusion analysis for healthcare systems worldwide, we take the next step in our mission to become a holistic brain solution provider,” says Wim Van Hecke, CEO at icometrix, Antwerp, Belgium. 

“The main challenge of current stroke solutions is correctly identifying the entry point of the injected contrast in the brain. icobrain cva introduces new, patented, deep learning technology into this identification process to achieve a more robust assessment of the infarcted area,” states Dirk Smeets, CTO at icometrix, Leuven, Belgium. 


LEAVE A REPLY

Please enter your comment!
Please enter your name here